05
Aug
2011
Posted in I - Series B, Q - 2Q11, R - INTERNATIONAL, X - Fibrinogen, X - Hemostasis
ProFibrix (Netherlands) a clinical-stage company focused on blood clotting and tissue healting, closed a $10.6M Series B financing, bringing the total round to $21.6M. Participants include Gilde Healthcare Partners and Index Ventures.